Aridis Pharmaceuticals (ARDS.US): Q2 reported revenue of $19.647 million in 2023, with a previous value of $292000, and earnings per share of $0.33, compared with a previous value of-45.
Aridis Pharmaceuticals(ARDS.US)：2023年Q2财报实现营收1964.7万美元，前值为29.2万美元；每股收益为0.33美元，前值为-0.45美元。
Aridis Pharmaceuticals (ARDS.US): The 2023 Q2 financial report achieved revenue of US$19647 million, a previous value of US$292,000; earnings per share was $0.33, and a previous value of -$0.45.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.